Pemetrexed plus carboplatin versus pemetrexed in pretreated patients with advanced non-squamous non-small-cell lung cancer: treating the right patients based on individualized treatment effect prediction

R. C. M. van Kruijsdijk, F. L. J. Visseren*, L. Boni, H. J. M. Groen, A. M. C. Dingemans, J. G. J. V. Aerts, Y. van der Graaf, A. Ardizzoni, E. F. Smit

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)1280-1286
JournalAnnals of Oncology
Volume27
Issue number7
DOIs
Publication statusPublished - Jul 2016

Keywords

  • pemetrexed
  • carboplatin
  • NSCLC
  • prediction
  • net benefit

Cite this